Results 91 to 100 of about 3,079,576 (204)

Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial [PDF]

open access: yes, 2019
Background Phenytoin is the recommended second-line intravenous anticonvulsant for treatment of paediatric convulsive status epilepticus in the UK; however, some evidence suggests that levetiracetam could be an effective and safer alternative. This trial
Mackle, Daisy   +99 more
core   +1 more source

Pediatric Absence Status Epilepticus: Prolonged Altered Mental Status in an 8-Year-Old Boy

open access: yesCase Reports in Neurological Medicine, 2016
Absence status epilepticus is characterized by a prolonged state of impaired consciousness or altered sensorium with generalized electroencephalographic abnormalities.
Scott J. Adams   +4 more
doaj   +1 more source

Risk of hostility and aggression with perampanel monotherapy versus combination therapy in pediatric epilepsy: A Japanese post‐marketing database study using a nested case–control design

open access: yesEpileptic Disorders, EarlyView.
Abstract Objective To compare the incidence of hostility‐ and aggression‐related adverse events in children with focal‐onset seizures (FOS), with or without focal to bilateral tonic–clonic seizures (FBTCS), receiving perampanel as monotherapy or in combination with other antiseizure medications (ASMs).
Yukitoshi Takahashi   +5 more
wiley   +1 more source

Therapeutic augmentation of ketogenic diet with a sodium-glucose cotransporter 2 inhibitor in a super-refractory status epilepticus patient

open access: yesEpilepsy and Behavior Case Reports, 2018
Background: A ketogenic diet (KD) may have a role in treating patients in super-refractory status epilepticus (SRSE). Sodium-glucose cotransporter 2 (SGLT2) inhibitors have a risk of ketoacidosis that could facilitate induction of KD.
Joseph R. Blunck   +3 more
doaj   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development

open access: yesEpilepsia, EarlyView.
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer   +7 more
wiley   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development

open access: yesEpilepsia, EarlyView.
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer   +7 more
wiley   +1 more source

Intraoperative electrocorticography guiding surgical resection in epilepsia partialis continua secondary to cardiac myxoma embolism: A clinical vignette

open access: yes
Epileptic Disorders, EarlyView.
Olalla Urdanibia‐Centelles   +7 more
wiley   +1 more source

Semiology of functional/dissociative seizures in idiopathic generalized epilepsy: An inpatient video‐electroencephalographic study

open access: yesEpilepsia, EarlyView.
Abstract Objective This study was undertaken to estimate the prevalence and characterize the semiology of co‐occurring functional/dissociative seizures (FDSs) and identify clinical features potentially associated with the development of video‐electroencephalography (video‐EEG)‐diagnosed FDSs in patients with idiopathic generalized epilepsy (IGE ...
Javier Peña‐Ceballos   +13 more
wiley   +1 more source

Prolonged fenfluramine use in open‐label studies of Dravet or Lennox–Gastaut syndromes: Long‐term safety, tolerability, patient global functioning, and considerations for interpreting effectiveness

open access: yesEpilepsia, EarlyView.
This graphical abstract provides an overview of the content from this open‐label extension study of fenfluramine use in patients with Dravet syndrome or Lennox‐Gastaut syndrome. Abstract Objective Long‐term safety and global functioning are reported in patients with Dravet syndrome (DS) or Lennox–Gastaut syndrome (LGS) treated with fenfluramine in an ...
Antonio Gil‐Nagel   +18 more
wiley   +1 more source

WONOEP appraisal: Biomarkers and treatment strategies beyond the synapse

open access: yesEpilepsia, EarlyView.
Abstract Epilepsy is a heterogeneous neurological disorder affecting more than 70 million people worldwide, posing significant challenges for clinicians due to its complex etiology, diverse manifestations, variable treatment responses, and the inability to predict seizures or disease onset reliably.
Mirte Scheper   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy